eCite Digital Repository

Comparison of markers of oxidative stress, inflammation and arterial stiffness between incident hemodialysis and peritoneal dialysis patients - an observational study

Citation

Fassett, RG and Driver, R and Healy, H and Ranganathan, D and Ratanjie, S and Robertson, IK and Geraghty, DP and Sharman, JE and Coombes, JS, Comparison of markers of oxidative stress, inflammation and arterial stiffness between incident hemodialysis and peritoneal dialysis patients - an observational study, BMC Nephrology, 10, (8) EJ ISSN 1471-2369 (2009) [Refereed Article]


Preview		PDF
248Kb		  

Copyright Statement

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Official URL: http://www.biomedcentral.com/1471-2369/10/8

DOI: doi:10.1186/1471-2369-10-8

Abstract

There is evidence that renal transplant recipients have accelerated atherosclerosis manifest by increased cardiovascular morbidity and mortality. The high incidence of atherosclerosis is, in part, related to increased arterial stiffness, vascular dysfunction, elevated oxidative stress and inflammation associated with immunosuppressive therapy. The dietary supplement astaxanthin has shown promise as an antioxidant and anti-inflammatory therapeutic agent in cardiovascular disease. The aim of this trial is to investigate the effects of astaxanthin supplementation on arterial stiffness, oxidative stress and inflammation in renal transplant patients. Method/Design This is a randomised, placebo controlled clinical trial. A total of 66 renal transplant recipients will be enrolled and allocated to receive either 12 mg/day of astaxanthin or an identical placebo for one-year. Patients will be stratified into four groups according to the type of immunosuppressant therapy they receive: 1) cyclosporine, 2) sirolimus, 3) tacrolimus or 4) prednisolone+/-azathioprine, mycophenolate mofetil or mycophenolate sodium. Primary outcome measures will be changes in 1) arterial stiffness measured by aortic pulse wave velocity (PWV), 2) oxidative stress assessed by plasma isoprostanes and 3) inflammation by plasma pentraxin 3. Secondary outcomes will include changes in vascular function assessed using the brachial artery reactivity (BAR) technique, carotid artery intimal medial thickness (CIMT), augmentation index (AIx), left ventricular afterload and additional measures of oxidative stress and inflammation. Patients will undergo these measures at baseline, six and 12 months. Discussion The results of this study will help determine the efficacy of astaxanthin on vascular structure, oxidative stress and inflammation in renal transplant patients. This may lead to a larger intervention trial assessing cardiovascular morbidity and mortality. Trial Registration - ACTRN12609000049279

Item Details

Item Type:Refereed Article
Keywords:renal transplant; antioxidant; vascular function
Research Division:Biomedical and Clinical Sciences
Research Group:Clinical sciences
Research Field:Nephrology and urology
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Robertson, IK (Dr Iain Robertson)
UTAS Author:Geraghty, DP (Professor Dominic Geraghty)
UTAS Author:Sharman, JE (Professor James Sharman)
ID Code:55213
Year Published:2009
Web of Science® Times Cited:12
Deposited By:Health Sciences A
Deposited On:2009-03-06
Last Modified:2010-05-27
Downloads:389 View Download Statistics

Repository Staff Only: item control page